Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14292897 | 0.96 | LMNA (0.63) | GLAGAALMNAPOLBSMARCA2 | |
| SCHEMBL8105059 | 0.91 | GLA (0.53) | GLAGAALMNAPOLBSMARCA2 | |
| SCHEMBL13941828 | 0.86 | LMNA (0.68) | GLAGAALMNAPOLBSMARCA2 | |
| SCHEMBL14564131 | 0.83 | KDM1A (0.58) | GLAGAALMNAPOLBSMARCA2 | |
| SCHEMBL8116591 | 0.83 | GLA (0.63) | GLAGAALMNAPOLBSMARCA2 | |
| SCHEMBL5438362 | 0.82 | GLA (0.58) | GLAGAALMNAPOLBSMARCA2 | |
| SCHEMBL3103845 | 0.82 | LMNA (0.61) | GLAGAALMNAPOLBSMARCA2 | |
| SCHEMBL30815826 | 0.82 | LMNA (0.61) | GLAGAALMNAPOLBSMARCA2 | |
| Hydrochloric Acid SCHEMBL3107661 | 0.81 | LMNA (0.64) | GLAGAALMNAPOLBSMARCA2 | |
| SCHEMBL11046169 | 0.80 | POLB (0.97) | GLAGAALMNAPOLBSMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101687859-A | Process for the preparation of alfuzosin and salts thereof | ACTAVIS GROUP PTC EHF | 2010-03-31 | — | — | CN | claimed |
| US-20090069562-A1 | Process for the preparation of alfuzosin | AUROBINDO PHARMA LTD (IN) | 2009-03-12 | — | — | US | claimed |
| WO-2023179068-A1 | DRUG INTERMEDIATE AND SYNTHETIC METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHETIC METHOD THEREFOR | 邦恩泰(山东)生物医药科技集团股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| EP-2178864-B1 | Process for the preparation of alfuzosin hydrochloride | CIPLA LTD (IN) | 2014-07-23 | — | — | EP | disclosed |
| US-8716476-B2 | Process for the preparation of alfuzosin hydrochloride | CIPLA LIMITED (IN) | 2014-05-06 | — | — | US | disclosed |
| US-8716476-B2 | Process for the preparation of alfuzosin hydrochloride | CIPLA LIMITED (IN) | 2014-05-06 | — | — | US | disclosed |
| US-8093384-B2 | Processes for the preparation of alfuzosin | WOCKHARDT LTD. (IN) | 2012-01-10 | — | — | US | disclosed |
| US-8093384-B2 | Processes for the preparation of alfuzosin | WOCKHARDT LTD. (IN) | 2012-01-10 | — | — | US | disclosed |
| US-20100256370-A1 | Process for the Preparation of Alfuzosin Hydrochloride | CIPLA LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-20100256370-A1 | Process for the Preparation of Alfuzosin Hydrochloride | CIPLA LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| CN-101687859-A | Process for the preparation of alfuzosin and salts thereof | ACTAVIS GROUP PTC EHF | 2010-03-31 | — | — | CN | disclosed |
| WO-2007144699-A2 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | TORRENT PHARMACEUTICALS LIMITED (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007074364-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | AUROBINDO PHARMA LIMITED (IN) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007069050-A2 | PROCESSES FOR THE PREPARATION OF ALFUZOSIN | WOCKHARDT LTD. (IN) | 2007-06-21 | — | — | WO | disclosed |
| US-20070105880-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | TORRENT PHARMACEUTICALS LIMITED (IN) | 2007-05-10 | — | — | US | disclosed |
| US-20070105880-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | TORRENT PHARMACEUTICALS LIMITED (IN) | 2007-05-10 | — | — | US | disclosed |
| US-20070066824-A1 | PREPARATION OF ALFUZOSIN | DR. REDDY'S LABORATORIES, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066824-A1 | PREPARATION OF ALFUZOSIN | DR. REDDY'S LABORATORIES, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066824-A1 | PREPARATION OF ALFUZOSIN | DR. REDDY'S LABORATORIES, INC. | 2007-03-22 | — | — | US | disclosed |
| WO-2006090268-A2 | PROCESSES FOR THE PREPARATION OF ALFUZOSIN AND SALTS THEREOF AND NOVEL CRYSTALLINE FORMS OF ALFUZOSIN | GLENMARK PHARMACEUTICALS LIMITED (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069562-A1 | Process for the preparation of alfuzosin | QDPR, OPRD1, OPRK1 | GLA 2843/4885GAA 2859/4885LMNA 544/4885 |
| US-20100256370-A1 | Process for the Preparation of Alfuzosin Hydrochloride | NEFM, HNMT, EPM2A | GLA 3710/4885GAA 3438/4885LMNA 84/4885 |
| US-20070105880-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | LPXN, PSAP, GYPA | GLA 2104/4885GAA 1107/4885LMNA 1437/4885 |
| US-20070066824-A1 | PREPARATION OF ALFUZOSIN | MAP7, LPXN, QDPR | GLA 3195/4885GAA 3711/4885LMNA 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.